Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
0 hedge funds and large institutions have $0 invested in Sciclone Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 128 closing their positions.
67.62% less ownership
Funds ownership: 67.62% → 0% (-68%)
100% less funds holding
Funds holding: 129 → 0 (-129)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $395M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 128
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$82.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$33.3M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$32.3M |
| 4 |
GLG Partners
London,
United Kingdom
|
-$29M |
| 5 |
State Street
Boston,
Massachusetts
|
-$18.5M |
SCLN Hedge Fund Activity: Q4 2017 in Review
0 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2017, worth a combined $0 — down 100% from $395M a quarter earlier.
Sellers outnumbered buyers: 128 funds closed out of SCLN and 0 opened new positions — a net loss of 128 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $82.1M sold.
- 0 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2017, down from 129 in Q3 2017.
- Funds reported $0 of Sciclone Pharmaceuticals Inc stock for Q4 2017, down 100% quarter-over-quarter.
- 0 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2017 and 128 closed out, a net change of -128 holders.
- The largest Sciclone Pharmaceuticals Inc seller in Q4 2017 was BlackRock, an estimated $82.1M sold.
Based on aggregated 13F filings for Q4 2017.